Insulin Versus Oral Hypoglycemic Agents in Gestational Diabetes Mellitus

In order to ascertain the relative safety and effectiveness of insulin and OHAs in the treatment of GDM, well-designed, prospective clinical trials are required. GDM is growing more common, and proper care is crucial to preventing complications. Although the evidence is conflicting, both therapy approaches might be beneficial. To maximize outcomes for both mother and child, evidence-based recommendations for pregnant women with GDM must close this knowledge gap. Comparing the effects of insulin and metformin in gestational diabetes mellitus is the rationale for this study. We can thus give our people a medication with less fetal adverse effects based on these findings. Based on this empirical data, we can then incorporate some useful suggestions into our standard practice guidelines for the use of the more effective medication of the two for gestational diabetes mellitus in order to lower perinatal mortality and fetal morbidity.

NCT Number	NCT07582471
Lead Sponsor	Dr Mudassar Saeed Pansota
Conditions	Gestational Diabetes Mellitus (GDM)
Enrollment	60 participants
Start Date	2025-10-08
Primary Completion	2026-04-07 (estimated)
Study Completion	2026-04-07 (estimated)
Updated on ClinicalTrials.gov	2026-05-14